SCHEMBL4354210

SCHEMBL4354210

CCN(CC(O)Cc1ccc([N+](=O)[O-])cc1)C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1D1 P20393 1/20 0.41
ALDH1A1 P00352 3/20 0.40
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
ITGA4 P13612 1/20 0.39
ITGB7 P26010 1/20 0.39
LMNA P02545 2/20 0.39
ADRB2 P07550 2/20 0.39
ADRB1 P08588 2/20 0.39
ADRB3 P13945 2/20 0.39
GAA P10253 2/20 0.38
MAPT P10636 1/20 0.38
BCL9 O00512 1/20 0.38
CTNNB1 P35222 1/20 0.38
TSHR P16473 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MMP1 P03956 1/20 0.37
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4348040 0.83 ADRB3 (0.41) PPARGPPARAADRB2ADRB1ADRB3
SCHEMBL1799639 0.83 NR1D1 (0.50) NR1D1ALDH1A1LMNAMAPTBCL9
SCHEMBL1993401 0.82 KCNH2 (0.47) NR1D1ALDH1A1PPARGPPARAADRB2
SCHEMBL16682350 0.79 NR1D1 (0.53) NR1D1ALDH1A1LMNAGAAMAPT
SCHEMBL16682346 0.78 NR1D1 (0.53) NR1D1ALDH1A1LMNAMAPTTSHR
SCHEMBL16796534 0.78 KCNH2 (0.50) NR1D1ALDH1A1PPARGPPARALMNA
SCHEMBL29070014 0.78 CA12 (0.48) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL3161371 0.76 NR1D1 (0.48) NR1D1ALDH1A1LMNAMAPTBCL9
SCHEMBL3129212 0.76 NR1D1 (0.48) NR1D1ALDH1A1LMNAMAPTTSHR
SCHEMBL19491362 0.75 KCNH2 (0.52) NR1D1ALDH1A1PPARGPPARALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 NR1D1 2070/4885ALDH1A1 915/4885PPARG 439/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 NR1D1 1926/4885ALDH1A1 1191/4885PPARG 1737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.